New therapeutic indications for botulinum toxins.
Identifieur interne : 000D86 ( Ncbi/Curation ); précédent : 000D85; suivant : 000D87New therapeutic indications for botulinum toxins.
Auteurs : Carla Cordivari [Royaume-Uni] ; V Peter Misra ; Santiago Catania ; Andrew J. LeesSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Anti-Dyskinesia Agents (pharmacology), Anti-Dyskinesia Agents (therapeutic use), Botulinum Toxins (pharmacology), Botulinum Toxins (therapeutic use), Drug Administration Routes, Dystonia (drug therapy), Humans, Pain (drug therapy), Parotid Gland (drug effects), Sialorrhea (drug therapy), Surgery, Plastic, Tremor (drug therapy).
- MESH :
- chemical , pharmacology : Anti-Dyskinesia Agents, Botulinum Toxins.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug effects : Parotid Gland.
- drug therapy : Dystonia, Pain, Sialorrhea, Tremor.
- Drug Administration Routes, Humans, Surgery, Plastic.
Abstract
The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic-mediated glandular function, and pain syndromes. The successful use of BTX in conditions with muscle overactivity, such as dystonia and spasticity, has been established and new areas in the field of movement disorders such as tics, tremor, myoclonic jerks, and stuttering has been explored with satisfactory results. Strategies to temporarily inactivate muscle function after orthopaedic or neurosurgery have also been developed. BTX treatment of hyperhidrosis was followed by its application in other hypersecretory conditions (hyperlacrimation and nasal hypersecretion) and in excessive drooling. Studies are in progress, aimed at optimising the technique and protocol of administration. Other applications for BTX have been proposed in gastroenterological and urogenital practice; it appears to be effective in replacing standard surgical procedures. Trials of BTX in painful conditions are ongoing mainly on refractory tension headache, migraine, and backache as well as dystonia-complex regional pain syndrome and myofascial pain with promising results. Recently, the fastest growing use for BTX toxin has been in the cosmetic applications. Clearly, the indications for the use of BTX are expanding, but further clinical trials will be needed in many different areas.
DOI: 10.1002/mds.20071
PubMed: 15027069
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003498
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003498
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003391
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000D86
Links to Exploration step
pubmed:15027069Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New therapeutic indications for botulinum toxins.</title><author><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V Peter" last="Misra">V Peter Misra</name></author><author><name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15027069</idno><idno type="pmid">15027069</idno><idno type="doi">10.1002/mds.20071</idno><idno type="wicri:Area/PubMed/Corpus">003498</idno><idno type="wicri:Area/PubMed/Curation">003498</idno><idno type="wicri:Area/PubMed/Checkpoint">003391</idno><idno type="wicri:Area/Ncbi/Merge">000D86</idno><idno type="wicri:Area/Ncbi/Curation">000D86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New therapeutic indications for botulinum toxins.</title><author><name sortKey="Cordivari, Carla" sort="Cordivari, Carla" uniqKey="Cordivari C" first="Carla" last="Cordivari">Carla Cordivari</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurophysiology, The National Hospital for Neurology and Neurosurgery, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Misra, V Peter" sort="Misra, V Peter" uniqKey="Misra V" first="V Peter" last="Misra">V Peter Misra</name></author><author><name sortKey="Catania, Santiago" sort="Catania, Santiago" uniqKey="Catania S" first="Santiago" last="Catania">Santiago Catania</name></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Dyskinesia Agents (pharmacology)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Botulinum Toxins (pharmacology)</term><term>Botulinum Toxins (therapeutic use)</term><term>Drug Administration Routes</term><term>Dystonia (drug therapy)</term><term>Humans</term><term>Pain (drug therapy)</term><term>Parotid Gland (drug effects)</term><term>Sialorrhea (drug therapy)</term><term>Surgery, Plastic</term><term>Tremor (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Parotid Gland</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term><term>Pain</term><term>Sialorrhea</term><term>Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Administration Routes</term><term>Humans</term><term>Surgery, Plastic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of botulinum toxin (BTX) without systemic effects has led to the rapid development of applications in neuromuscular disorders, hyperactivity of sudomotor cholinergic-mediated glandular function, and pain syndromes. The successful use of BTX in conditions with muscle overactivity, such as dystonia and spasticity, has been established and new areas in the field of movement disorders such as tics, tremor, myoclonic jerks, and stuttering has been explored with satisfactory results. Strategies to temporarily inactivate muscle function after orthopaedic or neurosurgery have also been developed. BTX treatment of hyperhidrosis was followed by its application in other hypersecretory conditions (hyperlacrimation and nasal hypersecretion) and in excessive drooling. Studies are in progress, aimed at optimising the technique and protocol of administration. Other applications for BTX have been proposed in gastroenterological and urogenital practice; it appears to be effective in replacing standard surgical procedures. Trials of BTX in painful conditions are ongoing mainly on refractory tension headache, migraine, and backache as well as dystonia-complex regional pain syndrome and myofascial pain with promising results. Recently, the fastest growing use for BTX toxin has been in the cosmetic applications. Clearly, the indications for the use of BTX are expanding, but further clinical trials will be needed in many different areas.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000D86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:15027069
|texte= New therapeutic indications for botulinum toxins.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15027069" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |